{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:46:39Z","timestamp":1790667999857,"version":"4.1.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,20]]},"DOI":"10.7759\/cureus.107411","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T20:14:41Z","timestamp":1776716081000},"source":"Crossref","is-referenced-by-count":1,"title":["Innovations in Refractory Melasma: Mechanism-Based Management and Emerging Therapeutic Strategies"],"prefix":"10.7759","author":[{"given":"Sof\u00eda","family":"Laguna Rocafort","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeevan","family":"Rivera-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid  M","family":"Bonilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Rabelo-Cartagena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1276906","article-title":"Prevalence of depression in melasma: a systematic review and meta-analysis","volume":"14","author":"Chen W","year":"2023","unstructured":"Chen W, Wan Y, Sun Y, Gao C, Li J. Prevalence of depression in melasma: a systematic review and meta-analysis. Front Psychiatry. 2023, 14:1276906. 10.3389\/fpsyt.2023.1276906","journal-title":"Front Psychiatry"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.0559","article-title":"Risk factors for keratinocyte carcinoma in recipients of allogeneic hematopoietic cell transplants","volume":"156","author":"Scott JF","year":"2020","unstructured":"Scott JF, Brough KR, Grigoryan KV, et al.. Risk factors for keratinocyte carcinoma in recipients of allogeneic hematopoietic cell transplants. JAMA Dermatol. 2020, 156:631-9. 10.1001\/jamadermatol.2020.0559","journal-title":"JAMA Dermatol"},{"key":"ref3","doi-asserted-by":"crossref","DOI":"10.5070\/D32510045810","article-title":"Melasma pathogenesis: a review of the latest research, pathological findings, and investigational therapies","volume":"25","author":"Rajanala S","year":"2019","unstructured":"Rajanala S, Maymone MB, Vashi NA. Melasma pathogenesis: a review of the latest research, pathological findings, and investigational therapies. Dermatol Online J. 2019, 25:13030\/qt47b7r28c.","journal-title":"Dermatol Online J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.14382","article-title":"The pathogenesis of melasma and implications for treatment","volume":"20","author":"Artzi O","year":"2021","unstructured":"Artzi O, Horovitz T, Bar-Ilan E, et al.. The pathogenesis of melasma and implications for treatment. J Cosmet Dermatol. 2021, 20:3432-45. 10.1111\/jocd.14382","journal-title":"J Cosmet Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s41073-019-0064-8","article-title":"SANRA-a scale for the quality assessment of narrative review articles","volume":"4","author":"Baethge C","year":"2019","unstructured":"Baethge C, Goldbeck-Wood S, Mertens S. SANRA-a scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 2019, 4:5. 10.1186\/s41073-019-0064-8","journal-title":"Res Integr Peer Rev"},{"key":"ref6","doi-asserted-by":"crossref","DOI":"10.4103\/jdds.jdds_44_23","article-title":"Melasma in the United States: a cross-sectional study of prevalence data using the All of Us database","volume":"27","author":"Verma KK","year":"2023","unstructured":"Verma KK, Dasuri VS, Friedmann DP. Melasma in the United States: a cross-sectional study of prevalence data using the All of Us database. J Dermatol Dermatol Surg. 2023, 27:76-7.","journal-title":"J Dermatol Dermatol Surg"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20143063","article-title":"Melasma: a clinical and epidemiological review","volume":"89","author":"Handel AC","year":"2014","unstructured":"Handel AC, Miot LD, Miot HA. Melasma: a clinical and epidemiological review. An Bras Dermatol. 2014, 89:771-82. 10.1590\/abd1806-4841.20143063","journal-title":"An Bras Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.8233","article-title":"The burden of melasma: race, ethnicity, and comorbidities","volume":"23","author":"Sharma AN","year":"2024","unstructured":"Sharma AN, Kincaid CM, Mesinkovska NA. The burden of melasma: race, ethnicity, and comorbidities. J Drugs Dermatol. 2024, 23:691-3. 10.36849\/JDD.8233","journal-title":"J Drugs Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/phpp.12783","article-title":"Melasma: The need for tailored photoprotection to improve clinical outcomes","volume":"38","author":"Morgado-Carrasco D","year":"2022","unstructured":"Morgado-Carrasco D, Piquero-Casals J, Granger C, Trull\u00e0s C, Passeron T. Melasma: The need for tailored photoprotection to improve clinical outcomes. Photodermatol Photoimmunol Photomed. 2022, 38:515-21. 10.1111\/phpp.12783","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.31557\/APJCP.2019.20.12.3723","article-title":"The role of stem cell factor in hyperpigmented skin lesions","volume":"20","author":"Atef A","year":"2019","unstructured":"Atef A, El-Rashidy MA, Abdel Azeem A, Kabel AM. The role of stem cell factor in hyperpigmented skin lesions. Asian Pac J Cancer Prev. 2019, 20:3723-8. 10.31557\/APJCP.2019.20.12.3723","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref11","doi-asserted-by":"crossref","DOI":"10.33192\/Smj.2021.109","article-title":"Melasma clinical features, diagnosis, epidemiology and etiology: an update review","volume":"73","author":"Abdalla MA","year":"2021","unstructured":"Abdalla MA. Melasma clinical features, diagnosis, epidemiology and etiology: an update review. Siriraj Medical Journal. 2021, 73:841-50.","journal-title":"Siriraj Medical Journal"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2023.06.003","article-title":"Chemical Peels in Treatment of Melasma","volume":"42","author":"Sarkar R","year":"2024","unstructured":"Sarkar R, Katoch S. Chemical Peels in Treatment of Melasma. Dermatol Clin. 2024, 42:21-32. 10.1016\/j.det.2023.06.003","journal-title":"Dermatol Clin"},{"key":"ref13","doi-asserted-by":"crossref","DOI":"10.3390\/app14167252","article-title":"Efficacy and tolerability of a microneedling device plus exosomes for treating melasma","volume":"14","author":"Proietti I","year":"2024","unstructured":"Proietti I, Battilotti C, Svara F, Innocenzi C, Spagnoli A, Potenza C. Efficacy and tolerability of a microneedling device plus exosomes for treating melasma. Applied Sciences. 2024, 14:7252.","journal-title":"Applied Sciences"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000042693","article-title":"Oral tranexamic acid, low-fluence intense pulsed light, and glycolic acid for the treatment of mixed melasma: an observational study","volume":"104","author":"Pan S","year":"2025","unstructured":"Pan S, Li M, Lu XY, Gao T. Oral tranexamic acid, low-fluence intense pulsed light, and glycolic acid for the treatment of mixed melasma: an observational study. Medicine (Baltimore). 2025, 104:e42693. 10.1097\/MD.0000000000042693","journal-title":"Medicine (Baltimore)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15287","article-title":"Evaluating the tolerance and efficacy of laser-assisted delivery of tranexamic acid, niacinamide, and kojic acid for melasma: a single center, prospective, split-face trial","volume":"35","author":"Park SJ","year":"2022","unstructured":"Park SJ, Park JW, Seo SJ, Park KY. Evaluating the tolerance and efficacy of laser-assisted delivery of tranexamic acid, niacinamide, and kojic acid for melasma: a single center, prospective, split-face trial. Dermatol Ther. 2022, 35:e15287. 10.1111\/dth.15287","journal-title":"Dermatol Ther"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15761","article-title":"Combination of autologous platelet rich plasma and hydroquinone 4% is more effective than hydroquinone alone in treatment of melasma: a split-face comparative study","volume":"35","author":"Tekam PS","year":"2022","unstructured":"Tekam PS, Belgaumkar VA. Combination of autologous platelet rich plasma and hydroquinone 4% is more effective than hydroquinone alone in treatment of melasma: a split-face comparative study. Dermatol Ther. 2022, 35:e15761. 10.1111\/dth.15761","journal-title":"Dermatol Ther"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14927","article-title":"The efficacy of energy-based devices combination therapy for melasma","volume":"34","author":"Iranmanesh B","year":"2021","unstructured":"Iranmanesh B, Khalili M, Mohammadi S, Amiri R, Aflatoonian M. The efficacy of energy-based devices combination therapy for melasma. Dermatol Ther. 2021, 34:e14927. 10.1111\/dth.14927","journal-title":"Dermatol Ther"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-024-00863-2","article-title":"An update on new and existing treatments for the management of melasma","volume":"25","author":"Gan C","year":"2024","unstructured":"Gan C, Rodrigues M. An update on new and existing treatments for the management of melasma. Am J Clin Dermatol. 2024, 25:717-33. 10.1007\/s40257-024-00863-2","journal-title":"Am J Clin Dermatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-019-00488-w","article-title":"Melasma treatment: an evidence-based review","volume":"21","author":"McKesey J","year":"2020","unstructured":"McKesey J, Tovar-Garza A, Pandya AG. Melasma treatment: an evidence-based review. Am J Clin Dermatol. 2020, 21:173-225. 10.1007\/s40257-019-00488-w","journal-title":"Am J Clin Dermatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.70066","article-title":"Delphi consensus on melasma management by international experts and pigmentary disorders society","volume":"40","author":"Sarkar R","year":"2026","unstructured":"Sarkar R, Desai SR, Sinha S, et al.. Delphi consensus on melasma management by international experts and pigmentary disorders society. J Eur Acad Dermatol Venereol. 2026, 40:680-92. 10.1111\/jdv.70066","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.16421","article-title":"Perspectives of topical formulations for melasma","volume":"62","author":"de Freitas AC","year":"2023","unstructured":"de Freitas AC, Rigon RB, Bagatin E, Leonardi GR. Perspectives of topical formulations for melasma. Int J Dermatol. 2023, 62:260-8. 10.1111\/ijd.16421","journal-title":"Int J Dermatol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.7104","article-title":"Optimizing melasma management with topical tranexamic acid: an expert consensus","volume":"22","author":"Desai S","year":"2023","unstructured":"Desai S, Chan L, Handog E, et al.. Optimizing melasma management with topical tranexamic acid: an expert consensus. J Drugs Dermatol. 2023, 22:386-92. 10.36849\/JDD.7104","journal-title":"J Drugs Dermatol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.713554","article-title":"Comparison of the efficacy of melasma treatments: a network meta-analysis of randomized controlled trials","volume":"8","author":"Liu Y","year":"2021","unstructured":"Liu Y, Wu S, Wu H, Liang X, Guo D, Zhou F. Comparison of the efficacy of melasma treatments: a network meta-analysis of randomized controlled trials. Front Med. 2021, 8:713554. 10.3389\/fmed.2021.713554","journal-title":"Front Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21244","article-title":"Self-applied topical interventions for melasma: a systematic review and meta-analysis of data from randomized, investigator-blinded clinical trials","volume":"187","author":"Pennitz A","year":"2022","unstructured":"Pennitz A, Kinberger M, Avila Valle G, Passeron T, Nast A, Werner RN. Self-applied topical interventions for melasma: a systematic review and meta-analysis of data from randomized, investigator-blinded clinical trials. Br J Dermatol. 2022, 187:309-17. 10.1111\/bjd.21244","journal-title":"Br J Dermatol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s10103-025-04529-1","article-title":"Fractional carbon dioxide laser assisted delivery of tranexamic acid versus ascorbic acid in the treatment of melasma: a split face comparative study with digital skin analysis","volume":"40","author":"Eassa BI","year":"2025","unstructured":"Eassa BI, Ammar AM, Shoaib OA, Elsaie ML. Fractional carbon dioxide laser assisted delivery of tranexamic acid versus ascorbic acid in the treatment of melasma: a split face comparative study with digital skin analysis. Lasers Med Sci. 2025, 40:282. 10.1007\/s10103-025-04529-1","journal-title":"Lasers Med Sci"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-024-03355-9","article-title":"Evaluation the efficacy of microneedling with topical metformin solution compared with microneedling with topical vitamin C solution in treatment of melasma","volume":"316","author":"Mahmoud MMY","year":"2024","unstructured":"Mahmoud MMY, Kamel AM, Galal SA. Evaluation the efficacy of microneedling with topical metformin solution compared with microneedling with topical vitamin C solution in treatment of melasma. Arch Dermatol Res. 2024, 316:662. 10.1007\/s00403-024-03355-9","journal-title":"Arch Dermatol Res"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15239","article-title":"Clinical, dermoscopic, and histopathologic evaluation of vitamin C versus PRP, with microneedling in the treatment of mixed melasma: a split-face, comparative study","volume":"35","author":"Abdel-Rahman AT","year":"2022","unstructured":"Abdel-Rahman AT, Abdel-Hakeem FG, Ragaie MH. Clinical, dermoscopic, and histopathologic evaluation of vitamin C versus PRP, with microneedling in the treatment of mixed melasma: a split-face, comparative study. Dermatol Ther. 2022, 35:e15239. 10.1111\/dth.15239","journal-title":"Dermatol Ther"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2022.2036872","article-title":"Magnesium ascorbyl phosphate vesicular carriers for topical delivery; preparation, in-vitro and ex-vivo evaluation, factorial optimization and clinical assessment in melasma patients","volume":"29","author":"Kandil SM","year":"2022","unstructured":"Kandil SM, Soliman II, Diab HM, Bedair NI, Mahrous MH, Abdou EM. Magnesium ascorbyl phosphate vesicular carriers for topical delivery; preparation, in-vitro and ex-vivo evaluation, factorial optimization and clinical assessment in melasma patients. Drug Deliv. 2022, 29:534-47. 10.1080\/10717544.2022.2036872","journal-title":"Drug Deliv"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-020-02133-7","article-title":"Clinical evaluation of efficacy and tolerability of cysteamine 5% cream in comparison with tranexamic acid mesotherapy in subjects with melasma: a single-blind, randomized clinical trial study","volume":"313","author":"Karrabi M","year":"2021","unstructured":"Karrabi M, Mansournia MA, Sharestanaki E, Abdollahnejad Y, Sahebkar M. Clinical evaluation of efficacy and tolerability of cysteamine 5% cream in comparison with tranexamic acid mesotherapy in subjects with melasma: a single-blind, randomized clinical trial study. Arch Dermatol Res. 2021, 313:539-47. 10.1007\/s00403-020-02133-7","journal-title":"Arch Dermatol Res"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.4103\/ijd.IJD_489_17","article-title":"Medical management of melasma: a review with consensus recommendations by Indian Pigmentary Expert Group","volume":"62","author":"Sarkar R","year":"2017","unstructured":"Sarkar R, Gokhale N, Godse K, et al.. Medical management of melasma: a review with consensus recommendations by Indian Pigmentary Expert Group. Indian J Dermatol. 2017, 62:558-77. 10.4103\/ijd.IJD_489_17","journal-title":"Indian J Dermatol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2018.12.006","article-title":"Kojic acid applications in cosmetic and pharmaceutical preparations","volume":"110","author":"Saeedi M","year":"2019","unstructured":"Saeedi M, Eslamifar M, Khezri K. Kojic acid applications in cosmetic and pharmaceutical preparations. Biomed Pharmacother. 2019, 110:582-93. 10.1016\/j.biopha.2018.12.006","journal-title":"Biomed Pharmacother"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.12147","article-title":"A double-blind, placebo-controlled randomized trial of Serratulae quinquefoliae folium, a new source of \u03b2-arbutin, in selected skin hyperpigmentations","volume":"14","author":"Morag M","year":"2015","unstructured":"Morag M, Nawrot J, Siatkowski I, et al.. A double-blind, placebo-controlled randomized trial of Serratulae quinquefoliae folium, a new source of \u03b2-arbutin, in selected skin hyperpigmentations. J Cosmet Dermatol. 2015, 14:185-90. 10.1111\/jocd.12147","journal-title":"J Cosmet Dermatol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2019.02.013","article-title":"Effective tyrosinase inhibition by thiamidol results in significant improvement of mild to\u00a0moderate melasma","volume":"139","author":"Arrowitz C","year":"2019","unstructured":"Arrowitz C, Schoelermann AM, Mann T, Jiang LI, Weber T, Kolbe L. Effective tyrosinase inhibition by thiamidol results in significant improvement of mild to\u00a0moderate melasma. J Invest Dermatol. 2019, 139:1691-8.e6. 10.1016\/j.jid.2019.02.013","journal-title":"J Invest Dermatol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.20471\/acc.2023.62.02.16","article-title":"The use of tranexamic acid in dermatology","volume":"62","author":"Ga\u0107ina K","year":"2023","unstructured":"Ga\u0107ina K, Krstanovi\u0107 \u0106osi\u0107 A. The use of tranexamic acid in dermatology. Acta Clin Croat. 2023, 62:368-72. 10.20471\/acc.2023.62.02.16","journal-title":"Acta Clin Croat"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.03.001","article-title":"Oral tranexamic acid (TA) in the treatment of melasma: A retrospective analysis","volume":"75","author":"Lee HC","year":"2016","unstructured":"Lee HC, Thng TG, Goh CL. Oral tranexamic acid (TA) in the treatment of melasma: A retrospective analysis. J Am Acad Dermatol. 2016, 75:385-92. 10.1016\/j.jaad.2016.03.001","journal-title":"J Am Acad Dermatol"},{"key":"ref36","article-title":"Melatonin: a paradigm shift in the management of melasma","volume":"42","author":"Malankar TE","year":"2023","unstructured":"Malankar TE, Thomas M, Gangawane AA, Rajpurohit L. Melatonin: a paradigm shift in the management of melasma. Am J Cosmet Surg. 2023, 42:","journal-title":"Am J Cosmet Surg"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19784","article-title":"Efficacy of oral 5\u2009mg melatonin in the treatment of facial melasma in women: A double-blind, randomized, placebo-controlled clinical trial","volume":"38","author":"Holanda IR","year":"2024","unstructured":"Holanda IR, de Almeida Corr\u00eaa Alfredo M, Cassiano DP, Esposito AC, Lima PB, Bagatin E, Miot HA. Efficacy of oral 5\u2009mg melatonin in the treatment of facial melasma in women: A double-blind, randomized, placebo-controlled clinical trial. J Eur Acad Dermatol Venereol. 2024, 38:e607-9. 10.1111\/jdv.19784","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000004167","article-title":"Chemical peels for melasma: a systematic review","volume":"50","author":"Sarkar R","year":"2024","unstructured":"Sarkar R, Lakhani R. Chemical peels for melasma: a systematic review. Dermatol Surg. 2024, 50:656-61. 10.1097\/DSS.0000000000004167","journal-title":"Dermatol Surg"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14693","article-title":"Most worthwhile superficial chemical peel for melasma of skin of color: Authors' experience of glycolic, trichloroacetic acid, and lactic peel","volume":"34","author":"Sahu P","year":"2021","unstructured":"Sahu P, Dayal S. Most worthwhile superficial chemical peel for melasma of skin of color: Authors' experience of glycolic, trichloroacetic acid, and lactic peel. Dermatol Ther. 2021, 34:e14693. 10.1111\/dth.14693","journal-title":"Dermatol Ther"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.4103\/ijdvl.IJDVL_1086_16","article-title":"Optimizing Q-switched lasers for melasma and acquired dermal melanoses","volume":"85","author":"Aurangabadkar SJ","year":"2019","unstructured":"Aurangabadkar SJ. Optimizing Q-switched lasers for melasma and acquired dermal melanoses. Indian J Dermatol Venereol Leprol. 2019, 85:10-7. 10.4103\/ijdvl.IJDVL_1086_16","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000000924","article-title":"Microneedling: a comprehensive review","volume":"43","author":"Hou A","year":"2017","unstructured":"Hou A, Cohen B, Haimovic A, Elbuluk N. Microneedling: a comprehensive review. Dermatol Surg. 2017, 43:321-39. 10.1097\/DSS.0000000000000924","journal-title":"Dermatol Surg"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000001248","article-title":"Microneedling: a review and practical guide","volume":"44","author":"Alster TS","year":"2018","unstructured":"Alster TS, Graham PM. Microneedling: a review and practical guide. Dermatol Surg. 2018, 44:397-404. 10.1097\/DSS.0000000000001248","journal-title":"Dermatol Surg"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000002763","article-title":"A systematic review of the efficacy and safety of microneedling in the treatment of melasma","volume":"46","author":"Wu SZ","year":"2020","unstructured":"Wu SZ, Muddasani S, Alam M. A systematic review of the efficacy and safety of microneedling in the treatment of melasma. Dermatol Surg. 2020, 46:1636-41. 10.1097\/DSS.0000000000002763","journal-title":"Dermatol Surg"},{"key":"ref44","article-title":"Topical treatments for melasma and their mechanism of action","volume":"15","author":"Gonz\u00e1lez-Molina V","year":"2022","unstructured":"Gonz\u00e1lez-Molina V, Mart\u00ed-Pineda A, Gonz\u00e1lez N. Topical treatments for melasma and their mechanism of action. J Clin Aesthet Dermatol. 2022, 15:19-28.","journal-title":"J Clin Aesthet Dermatol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2021.1914313","article-title":"Melasma treatment: a systematic review","volume":"33","author":"Neagu N","year":"2022","unstructured":"Neagu N, Conforti C, Agozzino M, et al.. Melasma treatment: a systematic review. J Dermatolog Treat. 2022, 33:1816-37. 10.1080\/09546634.2021.1914313","journal-title":"J Dermatolog Treat"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1097\/PRS.0000000000009994","article-title":"Comparison of picosecond and nanosecond Nd:YAG 1064-nm lasers in the treatment of melasma: a split-face randomized clinical trial","volume":"151","author":"Feng J","year":"2023","unstructured":"Feng J, Huang L. Comparison of picosecond and nanosecond Nd:YAG 1064-nm lasers in the treatment of melasma: a split-face randomized clinical trial. Plast Reconstr Surg. 2023, 151:772-7. 10.1097\/PRS.0000000000009994","journal-title":"Plast Reconstr Surg"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13051468","article-title":"Management of melasma: laser and other therapies - review study","volume":"13","author":"Jiryis B","year":"2024","unstructured":"Jiryis B, Toledano O, Avitan-Hersh E, Khamaysi Z. Management of melasma: laser and other therapies - review study. J Clin Med. 2024, 13:1468. 10.3390\/jcm13051468","journal-title":"J Clin Med"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1080\/14764172.2022.2099898","article-title":"Evaluation of platelet-rich plasma efficacy in melasma","volume":"24","author":"Acar A","year":"2022","unstructured":"Acar A, Ozturk A, Sokmen N, Unal I, Ertam Sagduyu I. Evaluation of platelet-rich plasma efficacy in melasma. J Cosmet Laser Ther. 2022, 24:36-9. 10.1080\/14764172.2022.2099898","journal-title":"J Cosmet Laser Ther"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-023-02580-y","article-title":"Intradermal injection of tranexamic acid versus platelet-rich plasma in the treatment of melasma: a split-face comparative study","volume":"315","author":"Abd Elraouf IG","year":"2023","unstructured":"Abd Elraouf IG, Obaid ZM, Fouda I. Intradermal injection of tranexamic acid versus platelet-rich plasma in the treatment of melasma: a split-face comparative study. Arch Dermatol Res. 2023, 315:1763-70. 10.1007\/s00403-023-02580-y","journal-title":"Arch Dermatol Res"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1781755","article-title":"Comparative study between topical tranexamic acid alone versus its combination with autologous platelet rich plasma for treatment of melasma","volume":"33","author":"Gamea MM","year":"2022","unstructured":"Gamea MM, Kamal DA, Donia AA, Hegab DS. Comparative study between topical tranexamic acid alone versus its combination with autologous platelet rich plasma for treatment of melasma. J Dermatolog Treat. 2022, 33:798-804. 10.1080\/09546634.2020.1781755","journal-title":"J Dermatolog Treat"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00575-z","article-title":"Efficacy and safety of platelet-rich plasma in melasma: a systematic review and meta-analysis","volume":"11","author":"Zhao L","year":"2021","unstructured":"Zhao L, Hu M, Xiao Q, Zhou R, Li Y, Xiong L, Li L. Efficacy and safety of platelet-rich plasma in melasma: a systematic review and meta-analysis. Dermatol Ther (Heidelb). 2021, 11:1587-97. 10.1007\/s13555-021-00575-z","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1007\/s10103-024-04066-3","article-title":"Definition of refractory melasma and its treatment: a review","volume":"39","author":"Yao H","year":"2024","unstructured":"Yao H, Shen S, Gao X, Feng J, Song X, Xiang W. Definition of refractory melasma and its treatment: a review. Lasers Med Sci. 2024, 39:118. 10.1007\/s10103-024-04066-3","journal-title":"Lasers Med Sci"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.70428","article-title":"Randomized clinical trial on the efficacy of oral tranexamic acid versus topical tranexamic acid in treatment of melasma","volume":"24","author":"Heidary B","year":"2025","unstructured":"Heidary B, Meibodi GA, Ardakani ME, Ramezani V, Heidari F. Randomized clinical trial on the efficacy of oral tranexamic acid versus topical tranexamic acid in treatment of melasma. J Cosmet Dermatol. 2025, 24:e70428. 10.1111\/jocd.70428","journal-title":"J Cosmet Dermatol"},{"key":"ref54","article-title":"Combination topical tranexamic acid and vitamin C for the treatment of refractory melasma","volume":"16","author":"Kaikati J","year":"2023","unstructured":"Kaikati J, El Bcherawi N, Khater JA, Dib SM, Kechichian E, Helou J. Combination topical tranexamic acid and vitamin C for the treatment of refractory melasma. J Clin Aesthet Dermatol. 2023, 16:63-5.","journal-title":"J Clin Aesthet Dermatol"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1337282","article-title":"Different therapeutic approaches in melasma: advances and limitations","volume":"15","author":"Ghasemiyeh P","year":"2024","unstructured":"Ghasemiyeh P, Fazlinejad R, Kiafar MR, Rasekh S, Mokhtarzadegan M, Mohammadi-Samani S. Different therapeutic approaches in melasma: advances and limitations. Front Pharmacol. 2024, 15:1337282. 10.3389\/fphar.2024.1337282","journal-title":"Front Pharmacol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/478222-innovations-in-refractory-melasma-mechanism-based-management-and-emerging-therapeutic-strategies","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T20:14:44Z","timestamp":1776716084000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/478222-innovations-in-refractory-melasma-mechanism-based-management-and-emerging-therapeutic-strategies"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":55,"URL":"https:\/\/doi.org\/10.7759\/cureus.107411","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,20]]}}}